ClinPGx Blog (Page 7)

Sign in Subscribe

More issues

Ask a Curator for Healthcare Professionals on June 7th

We are holding an Ask a Curator zoom targeted towards healthcare professionals wanting to learn more about PharmGKB and pharmacogenomics. This is part of NHGRI’s Healthcare Professionals Genomics Education Week (#MedGeneEd22). Be sure to spread the word to colleagues who may find this useful. We are asking people to

What does *1 really mean? And why does that matter?

A Haiku about PGx for National Poetry Month. Diagnosed star one, Yet severe toxicity. What did the lab test? What does *1 really mean? And why does that matter? The star alleles of the drug metabolizing enzyme genes are an unusual way of defining variation and are perhaps one of

Update to PharmGKB Pediatric Drug Summaries

The third round of PharmGKB's pediatric drug summaries is now live on PharmGKB pediatric. This release includes over 20 additional drugs with a focus on those on the Best Pharmaceuticals for Children Act (BPCA) priority list, including: * Albendazole * Amphotericin b * Artesunate * Atropine * Baclofen * Benznidazole * Betamethasone * Canakinumab * Cefepime * Ceftazidime

"Ask a Curator" live zoom event

PharmGKB curators will hold a series of live Q&A events over Zoom to help people find and use different aspects of the knowledgebase. We hope this will be a great way to answer questions about PharmGKB and PGx which are specific to users’ individual needs or projects. These

National Academy Seeking Public Feedback on Use of Population Descriptors in Genomics Research

The National Academy's Committee on Use of Race, Ethnicity, and Ancestry as Population Descriptors in Genomics Research is now actively requesting public comments from those involved in genomics research about how they use descriptors like race, ethnicity, and ancestry as well as thoughts on potential improvements to usage.

Retirement of CYP3A5 alleles in PharmVar

The PharmVar CYP3A5 expert panel has undertaken an extensive review of CYP3A5 allelic variation which led to the retirement of three star alleles, namely CYP3A5*2, *4 and *5. Based on new data, their defining variants were always found together with the CYP3A5*3-defining splice defect (c.219-237) meaning that

Update to individual statin pathways to support release of new CPIC guidelines for statins

To coincide with the release of the updated CPIC guidelines for SLCO1B1, ABCG2 and CYP2C9 and statin-associated musculoskeletal symptoms, we have updated the statin pharmacokinetic (PK) pathways. We now have one PK pathway for each individual drug in the guideline and have added details of the specific metabolites as well

CPIC Publishes Guideline for SLCO1B1, ABCG2, CYP2C9 and Statin Therapy

The CPIC guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (SAMS) has been published in the journal Clinical Pharmacology and Therapeutics. This guideline is an update to the CPIC guideline for simvastatin and SLCO1B1, but now includes expanded literature review on four additional genes, ABCG2, CYP2C9, HMGCR and

Registration opens for CPIC-PGRN 2022 meeting in Denver, Colorado

We are excited to announce that registration is open for the 2022 CPIC-PGRN meeting: Diversifying PGx Science to Improve Implementation. The meeting will be held at the University of Colorado on May 10th, 11th, and 12th in Denver, CO. Registration, agenda, and hotel information available at the meeting website. Early

PharmGKB Heparin-Induced Thrombocytopenia Pathway published

A PharmGKB pathway of heparin-induced thrombocytopenia (HIT) has been published in Pharmacogenetics and Genomics. Heparin is a commonly used anticoagulant. The pathway, written by Elise Miller along with other members of the Karnes lab at the University of Arizona as well as members of the PharmGKB team, outlines the atypical